FDA advisory committee

abecma
Pharma

FDA calls for adcomm on BMS's Abecma in earlier treatment line

BMS's effort to gain approval for Abecma in an earlier line of treatment—set for an FDA decision on Dec. 16—will be pushed back pending an FDA adcomm.
Kevin Dunleavy Nov 20, 2023 11:30am
FDA

FDA spotlights timely cancer accelerated approval confirmation

Nov 15, 2023 8:20am
Podcast
The Top Line

A look at FDA's Aduhelm approval and regulatory bias

Oct 27, 2023 8:00am
FDA

FDA flags 'systemic bias' in Amgen's Lumakras trial

Oct 3, 2023 2:23pm
FDA conference hall

Alnylam wins expert backing for Onpattro in rare heart disease

Sep 13, 2023 5:30pm
FDA

FDA casts doubt on Alnylam's Onpattro in ATTR-CM

Sep 11, 2023 11:15am